BACKGROUND: Thiopurine and allopurinol in combination are associated with clinical remission in inflammatory bowel diseases but their influence on subsequent outcomes is unclear. We compared outcomes during exposure to both thiopurines and allopurinol versus thiopurines alone. METHODS: We established a nationwide cohort of patients with inflammatory bowel diseases exposed to thiopurines ± allopurinol during 1999-2014, using registry data. Patients were followed until hospitalization, surgery, anti-TNFα, or death (as a primary composite outcome). We used Poisson regression analyses to calculate incidence rate ratios overall and stratified by calendar period (assuming the combined exposure was unintended before 2009). RESULTS: A total of 10,367 patients with inflammatory bowel diseases (Crohn's disease, n = 5484; ulcerative colitis, n = 4883) received thiopurines. Of these, 217 (2.1%) also received allopurinol. During 24,714 person years of follow-up, we observed 40 outcomes among thiopurine-allopurinol-exposed patients, and 4745 outcomes among those who were thiopurine exposed; incidence rate ratio, 1.26 (95% confidence interval, 0.92-1.73). The incidence rate ratios decreased over time: 4.88 (95% confidence interval 2.53-9.45) for 1999-2003, 2.19 (95% confidence interval, 1.17-4.09) for 2004-2008 and 0.80 (95% confidence interval, 0.52-1.23) for 2009-2014. CONCLUSION: Our nationwide inflammatory bowel disease cohort study shows that concomitant thiopurine-allopurinol is as safe to use as thiopurines alone, with a tendency towards a positive effect on clinical outcomes in recent calendar periods when combined use was intended.
BACKGROUND:Thiopurine and allopurinol in combination are associated with clinical remission in inflammatory bowel diseases but their influence on subsequent outcomes is unclear. We compared outcomes during exposure to both thiopurines and allopurinol versus thiopurines alone. METHODS: We established a nationwide cohort of patients with inflammatory bowel diseases exposed to thiopurines ± allopurinol during 1999-2014, using registry data. Patients were followed until hospitalization, surgery, anti-TNFα, or death (as a primary composite outcome). We used Poisson regression analyses to calculate incidence rate ratios overall and stratified by calendar period (assuming the combined exposure was unintended before 2009). RESULTS: A total of 10,367 patients with inflammatory bowel diseases (Crohn's disease, n = 5484; ulcerative colitis, n = 4883) received thiopurines. Of these, 217 (2.1%) also received allopurinol. During 24,714 person years of follow-up, we observed 40 outcomes among thiopurine-allopurinol-exposed patients, and 4745 outcomes among those who were thiopurine exposed; incidence rate ratio, 1.26 (95% confidence interval, 0.92-1.73). The incidence rate ratios decreased over time: 4.88 (95% confidence interval 2.53-9.45) for 1999-2003, 2.19 (95% confidence interval, 1.17-4.09) for 2004-2008 and 0.80 (95% confidence interval, 0.52-1.23) for 2009-2014. CONCLUSION: Our nationwide inflammatory bowel disease cohort study shows that concomitant thiopurine-allopurinol is as safe to use as thiopurines alone, with a tendency towards a positive effect on clinical outcomes in recent calendar periods when combined use was intended.
Authors: Frank Hoentjen; Margien L Seinen; Stephen B Hanauer; Nanne K H de Boer; David T Rubin; Gerd Bouma; Laura E Harrell; Adriaan A van Bodegraven Journal: Inflamm Bowel Dis Date: 2013-02 Impact factor: 5.325
Authors: Jean Frédéric Colombel; William J Sandborn; Walter Reinisch; Gerassimos J Mantzaris; Asher Kornbluth; Daniel Rachmilewitz; Simon Lichtiger; Geert D'Haens; Robert H Diamond; Delma L Broussard; Kezhen L Tang; C Janneke van der Woude; Paul Rutgeerts Journal: N Engl J Med Date: 2010-04-15 Impact factor: 91.245
Authors: A B Friedman; S J Brown; P Bampton; M L Barclay; A Chung; F A Macrae; J McKenzie; J Reynolds; P R Gibson; S B Hanauer; M P Sparrow Journal: Aliment Pharmacol Ther Date: 2018-02-21 Impact factor: 8.171
Authors: M P Sparrow; S A Hande; S Friedman; W C Lim; S I Reddy; D Cao; S B Hanauer Journal: Aliment Pharmacol Ther Date: 2005-09-01 Impact factor: 8.171
Authors: Julián Panés; Antonio López-Sanromán; Fernando Bermejo; Valle García-Sánchez; Maria Esteve; Yolanda Torres; Eugeni Domènech; Marta Piqueras; María Gomez-García; Ana Gutiérrez; Carlos Taxonera; Miquel Sans Journal: Gastroenterology Date: 2013-06-13 Impact factor: 22.682
Authors: B Lo; M V Prosberg; L L Gluud; W Chan; R W Leong; E van der List; M van der Have; H Sarter; C Gower-Rousseau; L Peyrin-Biroulet; I Vind; J Burisch Journal: Aliment Pharmacol Ther Date: 2017-10-09 Impact factor: 8.171
Authors: V Chhaya; S Saxena; E Cecil; S Chatu; V Subramanian; V Curcin; A Majeed; R C Pollok Journal: Aliment Pharmacol Ther Date: 2014-11-10 Impact factor: 8.171
Authors: Fernando Magro; Catarina Alves; Mafalda Santiago; Paula Ministro; Paula Lago; Luís Correia; Raquel Gonçalves; Diana Carvalho; Francisco Portela; Cláudia Camila Dias; Axel Dignass; Silvio Danese; Laurent Peyrin-Biroulet; Maria Manuela Estevinho; Paula Moreira Journal: United European Gastroenterol J Date: 2021-12-14 Impact factor: 4.623
Authors: Rahma Elmahdi; Louise T Thomsen; Aske T Iversen; Kristine H Allin; Susanne K Kjaer; Tine Jess Journal: United European Gastroenterol J Date: 2022-03-16 Impact factor: 4.623
Authors: Marianne Kiszka-Kanowitz; Klaus Theede; Sandra Bohn Thomsen; Jacob Tveiten Bjerrum; Jørn Brynskov; Ida Benedikte Gottschalck; Elena Akimenko; Karen Lisa Hilsted; Anders Neumann; Signe Wildt; Lone Larsen; Jens Kristian Munk; Per Holger Ibsen; Huma Gul Rehana Janjua; Lise Lotte Gluud; Anette Mertz-Nielsen Journal: EClinicalMedicine Date: 2022-03-05